<DOC>
	<DOCNO>NCT02986620</DOCNO>
	<brief_summary>This study intervention plan . Investigators collect data already patient 's history analyze . Particularly , interested molecular data AML patient . This mean patient follow regular diagnostic clinical practice . The analysis conduct accord routine diagnostic clinical practice well additional blood withdrawal perform .</brief_summary>
	<brief_title>Italian Registry Prevalence IDH1/IDH2 Mutations Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>The study conduct follow : 1 . Retrospective phase clinical molecular data patient analyze IDH1/2 mutation retrospectively collect center already introduce IDH1/2 mutational screening practice case collect accord standard procedure ( Ficoll lysis RLT buffer ) . 2 . Prospective phase : participating center already perform IDH1/2 mutational status sample AML patient diagnosis relapse - freshly isolate mononuclear cell bone marrow and/or peripheral blood use Ficoll density gradient preparation - prospectively collect clinical molecular data .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion criterion : Signed write informed consent accord ICH/EU/GCP national local law ( applicable ) ; AML patient ; Age â‰¥18 ; IDH mutation test perform diagnosis relapse January 31st , 2019 . Exclusion criterion : AML M3 subtype accord FAB classification ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>